Lazibat Ines, Nevajda Branimir, Grahovac Gordan, Brinar Vesna V
Coll Antropol. 2014 Mar;38(1):385-93.
MS is a chronic, increasingly disabling disease whose long-term outcomes determine the key social, medical and economic impact of this disease. Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are prescribed to delay disease progression and to protect a patient's functional capability. The concepts of escalation and induction immunotherapy in MS represent different therapeutic strategies for the treatment of MS. Both strategies may be valuable options for patients starting on DMT, however, induction therapy mainly focuses on patients with very aggressive course of MS from the onset. Using a patient unique approach to selection of treatment, MS can be effectively control disease and may delay or even prevent the development of secondary progressive MS.
多发性硬化症（MS）是一种慢性且致残性日益增加的疾病，其长期预后决定了该疾病对社会、医疗和经济的关键影响。针对多发性硬化症（MS）的疾病修正疗法（DMTs）被用于延缓疾病进展并保护患者的功能能力。MS中的强化和诱导免疫疗法概念代表了治疗MS的不同治疗策略。这两种策略对于开始使用DMT的患者而言可能都是有价值的选择，然而，诱导疗法主要针对从疾病发作起病程就非常侵袭性的患者。采用针对患者个体的治疗选择方法，可以有效控制MS疾病，并可能延缓甚至预防继发进展型MS的发展。
